tiprankstipranks

Corcept Therapeutics price target raised to $142 from $130 at Canaccord

Canaccord raised the firm’s price target on Corcept Therapeutics (CORT) to $142 from $130 and keeps a Buy rating on the shares. The firm’s target changed following an update to its model as a result of the positive Phase III ROSELLA outcome. They continue to be bullish on the shares given the strength of uptake in Korlym over the past two years. They believe the market potential for Korlym is quite significant and that their model projections are conservative.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue